(S)-4-(6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl)-N-methyl-N-(pyrrolidin-2-ylmethyl)benzamide | 1272598-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (S)-4-(6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl)-N-methyl-N-(pyrrolidin-2-ylmethyl)benzamide
• 英文别名: 4-[6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl]-N-methyl-N-[[(2S)-pyrrolidin-2-yl]methyl]benzamide
• CAS: 1272598-44-3
• 化学式: C₂₃H₂₈N₆O
• 分子量: 404.515
• InChiKey: AKWSIDWVFMPINB-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (S)-2-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 在 盐酸 、 sodium hydride 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-4-(6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl)-N-methyl-N-(pyrrolidin-2-ylmethyl)benzamide
  参考文献：
  名称：

  Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo

  摘要：

  We have increased the potency of imidazo[1,2-b]pyridazine derivatives as IKK beta inhibitors with two strategies. One is to enhance the activity in cell-based assay by adjusting the polarity of molecules to improve permeability. Another is to increase the affinity for IKK beta by the introduction of additional substituents based on the hypothesis derived from an interaction model study. These improved compounds showed inhibitory activity of TNF alpha production in mice. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.078

文献信息

• Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo
  作者：Hiroki Shimizu、Isao Yasumatsu、Tomoaki Hamada、Yoshiyuki Yoneda、Tomonori Yamasaki、Shinji Tanaka、Tadashi Toki、Mika Yokoyama、Kaoru Morishita、Shin Iimura

  DOI：10.1016/j.bmcl.2010.12.078

  日期：2011.2

  We have increased the potency of imidazo[1,2-b]pyridazine derivatives as IKK beta inhibitors with two strategies. One is to enhance the activity in cell-based assay by adjusting the polarity of molecules to improve permeability. Another is to increase the affinity for IKK beta by the introduction of additional substituents based on the hypothesis derived from an interaction model study. These improved compounds showed inhibitory activity of TNF alpha production in mice. (C) 2010 Elsevier Ltd. All rights reserved.